RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis

See allHide authors and affiliations

Science Translational Medicine  25 Jan 2017:
Vol. 9, Issue 374, eaai9338
DOI: 10.1126/scitranslmed.aai9338

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A new way to resorb bone

Although bone seems inert, it is in fact in constant flux, being continuously deposited by cells called osteoblasts and broken down by osteoclasts. Andrade et al. show that the bone degeneration seen in diseases, such as cancer and osteoporosis, is caused at least partly by an overexuberant, bone-destroying pathway in which a signaling molecule, MSP, activates its receptor, RON tyrosine kinase, on host cells. Blocking of this signaling by genetic or pharmacologic means prevents bone breakdown in mouse models of metastasis and estrogen- depletion osteoporosis. This welcome approach may work in humans too: A RON kinase inhibitor reduced markers of bone turnover in postmenopausal women.